BRIEF-Aeterna zentaris Q3 loss per share $0.61
November 08, 2016 at 17:00 PM EST
* Aeterna Zentaris - believe have funds necessary to complete two pivotal clinical trials, to report top-line results on both, to file a nda for macrilen in first half of 2017
